ClinicalTrials.gg
CompletedNCT06619054Updated Oct 31, 2025

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

A Phase 1 interventional study of KP-001 in Healthy Adults and Hepatic Impairment, sponsored by Kaken Pharmaceutical. Completed at 1 site in United States. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-31.

Sponsored by Kaken Pharmaceutical · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

This is a phase 1, open-label, non-randomized, parallel-group, single-dose study to assess the effect of hepatic impairment (assessed by the criteria of the Child-Pugh scale) on the pharmacokinetics (PK) and safety of KP-001 in adult male and non-childbearing potential female participants aged ≥20 years old.

The purpose of this study is to evaluate the effect of hepatic impairment on the PK and safety of KP-001. The study will also assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001.

The study will comprise 3 parts, and the study period for each part will consist of the following:

  • Screening period: Up to 28 days before the administration of study intervention
  • Treatment Period: Participants will be residential at the Clinical Unit from the day before the administration of the single dose of KP-001 (Day -1) until Day 3 (Discharge)
  • Follow-up Visit: 7 days after discharge from the Clinical Unit (ie, Day 10) Participants will be enrolled into 4 cohorts according to the hepatic function status as summarized below. The study includes a control group of healthy participants with normal hepatic function.
02

Conditions studied

  • Healthy Adults
  • Hepatic Impairment
03

In context

Lead sponsor

Kaken Pharmaceutical is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

・All Participants (Cohorts 1 to 4)

  1. Participant is male or female and aged ≥20 years old at the time of signing the .
  2. Participant has body weight ≥40.0 kg and between 18.0 and 42.0 kg/m2 at screening.
  3. Female participant is a woman of non- who:

    1. Is with amenorrhea for at least 1 year prior to screening and with FSH of 40 IU/L or higher.

      OR

    2. Has undergone one of the following:

      • bilateral tubal ligation or bilateral salpingectomy
      • hysterectomy
      • bilateral oophorectomy
  4. Male participant who is sexually active with female partner(s) of childbearing potential must agree to use both a condom and spermicide from the day of the administration of KP-001 until 91 days after the administration of KP-001.
  5. Male participant must agree to not donate sperm from the day of the administration of KP-001 until 91 days after the administration of KP-001.
  6. Participant is capable of giving signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

    ・Healthy Participants with Normal Hepatic Function (Cohort 1)

  7. Participant is of a gender matched to his/her matched participant enrolled in Cohort 3.
  8. Participant is of an age that is within ±10 years to his/her matched participant enrolled in Cohort 3.
  9. Participant has a body mass index within ±20% to his/her matched participant enrolled in Cohort 3.
  10. Participant is medically healthy with no abnormal screening results (e.g., medical history, physical examination, laboratory profiles, vital signs, or ECGs), in the opinion of the Investigator or designee.

    If screening and/or admission results are abnormal, they may be repeated once at screening and/or once at admission to confirm the participant's eligibility.

  11. Participant whose and ALT at screening and admission meet the following: ALT and AST \< 2 .
  12. Participant has negative results for , , and antibody screens.
  13. Non-smoker and no use of other tobacco- or nicotine-containing products, as documented by history (no tobacco or nicotine use within 6 months prior to Screening) during the study.

    ・Participants with Hepatic Impairment (Cohorts 2 to 4)

  14. Participant whose classification at screening and admission laboratory tests applies to any of the following:

    • Cohort 2: Child-Pugh Grade A (score 5-6)
    • Cohort 3: Child-Pugh Grade B (score 7-9)
    • Cohort 4: Child-Pugh Grade C (score 10-15)
  15. Participant considered by the Investigator to be clinically stable with respect to underlying hepatic impairment, based on medical evaluation that includes medical and surgical history, as well as a complete physical examination including seated vital signs, 12-lead , and laboratory test results.
  16. Participant whose laboratory abnormalities are judged by the investigator to be clinically acceptable.
  17. Participant has no clinical exacerbation of hepatic disease within 30 days prior to study intervention administration.
  18. Participant with negative hepatitis B surface antigen (HBsAg) at screening.
  19. Non-smoker and no use of other tobacco or nicotine-containing products during the study.

Exclusion criteria

Exclusion Criteria:

・All Participants (Cohorts 1 to 4)

  1. Participant has a history or presence of or idiosyncratic reaction to any components of the KP-001 formulation or any components of formulation used as study intervention during the study.
  2. Participant has a complication of drug allergies or history of drug allergies, or psychiatric disorder as determined by the Investigator or designee.
  3. Participant used any drug in the last 30 days or 5 half-lives (if known), whichever is longer, prior to Day -1 of Treatment Period.
  4. Female participant has a positive pregnancy test or is lactating.
  5. Participant has positive urine drug or urine alcohol and positive cotinine test results at screening or Day -1 of Treatment Period.
  6. Participant who cannot administer drugs orally.
  7. Participant is unable or unwilling to undergo multiple venipunctures.
  8. Participant underwent blood donation or transfusion within 56 days prior to Day -1 of Treatment Period.
  9. Participant has consumed alcohol- or caffeine-containing foods and beverages within 72 hours prior to Day -1 of Treatment Period and does not agree to refrain from consuming during the entire study, unless deemed acceptable by the Investigator.
  10. Participant has consumed grapefruit-containing foods and beverages within 7 days prior to Day -1 of Treatment Period and does not agree to refrain from consuming during the entire study.
  11. Participant has consumed St. John's wort-containing foods and beverages within 14 days prior to Day -1 of Treatment Period and does not agree to refrain from consuming during the entire study.
  12. Participated in strenuous exercise from 48 hours prior to Check-in (Day -1) or during the study through the final end of study assessment.
  13. Participant is legally, mentally or physically incapacitated or, in the opinion of the Investigator, has significant mental or emotional problems, including psychiatric illness (e.g., depression and/or anxiety) at the time of the Screening Visit, or that could reasonably be expected to develop during the conduct of the study.
  14. Participant had any laboratory abnormality that, in the judgment of the Investigator, would put the participant at unacceptable risk for participation in the study or may interfere with the assessments included in the study.
  15. Participant has abnormal findings on the screening deemed by the Investigator or qualified designee.
  16. Participant is an employee of the Sponsor or any CRO involved in the study, the Investigator, or an immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of an employee involved in the study.
  17. Any other reason that would render the participant unsuitable for study enrollment at the discretion of the Investigator.
  18. A participant who has received proton pump inhibitors (PPIs), histamine type-2 (H2)-receptor antagonists, or antacids during the 5-day period immediately preceding and including the admission day (or for 5 half-lives of the medication whichever is longer), or plan to receive any of these medications during treatment period (ie, until Day 3 [Discharge]).

    ・Healthy Participants with Normal Hepatic Function (Cohort 1)

  19. Participant has a significant history or clinical manifestation of any metabolic, allergic, dermatologic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder as determined by the Investigator or designee.
  20. Participant has a history of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  21. Participant had any major illness within 30 days before the Screening Visit.
  22. Participant had any major surgical procedure within 30 days prior to Day -1 of Treatment Period or any planned surgery during study period.
  23. Participant has a history or presence of liver disease or cholecystectomy within one year prior to screening.
  24. Participant has a disorder or any condition that would interfere with the absorption, distribution, metabolism, or excretion of drugs.
  25. Participant used any prescription or non-prescription medications (including vitamins, recreational drugs, and dietary or herbal supplements) within 14 days or 5 half-lives (whichever is longer) prior to Day -1 of Treatment Period and until completion of the Followup Visit unless, in the opinion of the Investigator, may be treatment for an AE or will not interfere with the interpretation of safety.

    ・Participants with Hepatic Impairment (Cohorts 2 to 4)

  26. Participant with any concomitant disease or condition considered clinically significant that, in the opinion of the investigator, may interfere with the investigational product, pose an unacceptable risk to the participant, or significantly increase the risk to the integrity or utility of the trial data (including treatment of such conditions).
  27. Participant with acute or chronic conditions other than liver (including, but not limited to, poorly controlled diabetes and grade 3 or higher encephalopathy) that, in the opinion of the investigator, would limit the participant\'s ability to complete the study and/or participate in this study.
  28. Participant with acute exacerbation of liver dysfunction or unstable liver function as determined by the investigator by Day 1 from screening.
  29. Participant who is positive for , or at screening. Participants with hepatitis C will also be accepted if, in the investigator\'s judgement, they are clinically stable and not receiving active treatment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort1 (Normal)

    Child-Pugh Score: N/A

    Drug: KP-001

  • Experimental
    Cohort2 (Mild Impairment)

    Child-Pugh Score: A (5 to 6 points)

    Drug: KP-001

  • Experimental
    Cohort3 (Moderate Impairment)

    Child-Pugh Score: B (7 to 9 points)

    Drug: KP-001

  • Experimental
    Cohort4 (Severe Impairment)

    Child-Pugh Score: C (10 to 15 points)

    Drug: KP-001

Interventions

  • DrugKP-001

    Oral single dose 50mg.

06

What researchers measure

Primary outcomes

  1. PK parameters of KP-001 in plasma: Cmax

    To evaluate the effect of hepatic impairment on the PK and safety of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  2. PK parameters of KP-001 in plasma:AUC0-inf

    To evaluate the effect of hepatic impairment on the PK and safety of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

Secondary outcomes

  1. PK parameters of KP-001 in plasma: AUC0-last

    To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  2. PK parameters of KP-001 in plasma: t1/2

    To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  3. PK parameters of KP-001 in plasma: λz

    To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  4. PK parameters of KP-001 in plasma: CL/F

    To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  5. PK parameters of KP-001 in plasma: Vz/F

    To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  6. PK parameters of KP-001 in plasma: Tmax

    To assess the effect of hepatic impairment on other PK parameters after single dose administration of KP-001

    Time frame: pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

07

Study locations

1 site
  • Sites contracted by Parexel
    San Antonio, Texas 08103, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in May 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Oct 1, 2024
StartActual
Oct 24, 2024
Primary completionActual
May 16, 2025
CompletionActual
Jul 31, 2025
Last update
Oct 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06619054
Lead sponsor
Kaken Pharmaceutical
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Oct 24, 2024
Primary completion
May 16, 2025
Completion
Jul 31, 2025
Last update
Oct 31, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KP-001

Start the discussion